Cancerele capului şi gâtului în contextul pandemiei cu SARS-CoV-2. Provocări şi capcane

 Head and neck cancers in the context of SARS-CoV-2 pandemic. Challenges and pitfalls

First published: 24 aprilie 2021

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/OnHe.55.2.2021.5016


The treatment and diagnosis of patients with head and neck cancers are a challenge in the SARS-CoV-2 pandemic context, due to the therapeutic and prognostic features, with a risk of evolution to more advanced stages and, consequently, with a high mortality in case of delayed treatment. Head and neck cancers, in particular squamous cell carcinoma (HNSSC), are an oncological pathology that must be prioritized in terms of evaluation and treatment, even in the context of pan­de­mic outbreaks. It is thus estimated an increase of more ex­ten­sive surgical treatments and definitive nonsurgical treatments. Data on the association of SARS-CoV-2 infection with head and neck cancers are limited to case studies, with more se­vere progression anticipated by severe pneumonia and comorbidities decompensation, and less by the ef­fects on the “cytokine storm”, taking into account the im­mu­no­suppressive sta­tus characteristic to neoplasia. An increased attention re­gar­ding the infectious risk should be paid to can­cers of oral ca­vi­ty, through the possible molecular mechanisms involved. In case of SARS-CoV-2 infection, the re­duc­tion of smoking and al­co­hol con­sum­ption, rigorous oral hygiene, aggressive ma­­nage­­ment of comorbidities, and the immediate practice of tracheo­stomy in case of clear indication are measures that can reduce the risk of prolonged hospitalization in intensive care units and can re­duce the mortality of neoplastic patients. It is necessary to eva­luate in clinical trials groups of patients who associate head and neck cancers and COVID-19, in order to elucidate both the pathophysiological hypotheses and the risk of sy­nergic effects of the two diseases. 

head and neck cancers, COVID-19, oncological surgery, adjuvant treatment, SARS-CoV-2


Tratamentul şi diagnosticul neoplasmelor capului şi gâtului reprezintă o provocare în contextul pandemic cauzat de SARS-CoV-2, prin particularităţile diagnostice terapeutice şi prog­nos­tice, prin riscul de evoluţie către stadii mai avansate şi, în consecinţă, către o  mortalitatea ridicată în cazul amânării tra­ta­mentului. Cancerele capului şi gâtului, în particular car­ci­no­mul scuamos al capului şi gâtului (HNSCC), reprezintă o patologie oncologică ce trebuie prioritizată din punctul de ve­de­re al  evaluării şi tratamentului chiar şi în contextul fo­ca­relor pan­demice. Se estimează, astfel, creşterea necesităţii tra­ta­men­telor chirurgiale ample, cât şi a tratamentelor definitive ne­chi­rur­gi­cale. Datele referitoare la asocierea infecţiei cu SARS-CoV-2 cu neoplasmele capului şi gâtului sunt reduse şi limitate la studii de caz, o evoluţie mai severă fiind anticipată prin pneumonii severe şi decompensări ale comorbidităţilor, mai puţin prin efectele „fur­tunii de citokine”, având în vedere statusul de imunosupresie ca­rac­teristic neoplaziei. O atenţie sporită în ceea ce priveşte ris­­cul de infecţie trebuie acordată cancerelor cavităţii orale, prin po­si­bi­lele mecanisme moleculare implicate. În cazul infecţiei cu SARS-CoV-2, reducerea fumatului, a consumului de alcool, igiena ora­lă riguroasă, managementul agresiv al comorbidităţilor şi prac­ti­carea imediată a traheostomei în cazul unei indicaţii clare sunt măsuri care pot diminua riscul unei internări prelungite în de­par­tamentele de terapie intensivă şi care pot reduce mortalitatea pa­cien­ţilor neoplazici. Este necesară evaluarea în cadrul studiilor cli­ni­ce a unor loturi de pacienţi care asociază cancere ale ca­pu­lui şi gâtului şi COVID-19, pentru a elucida atât ipotezele fizio­pa­to­lo­gice, cât şi riscul efectelor sinergice ale celor două boli. 


The treatment and diagnosis of patients with head and neck cancers are a challenge in the SARS-CoV-2 pandemic context due to the therapeutic and prognostic features, with a risk of evolution to more advanced stages and, consequently, with a high mortality in case of delayed treatment, by limiting the resources of the medical systems that were prioritized for the treatment of COVID-19 patients. The increased risk, up to two times, to develop severe forms of disease also contributes to the limitation of medical care of cancer patients in this context. Due to the risk of SARS-CoV-2 contamination of both medical staff involved and patients, associated with invasive procedures, but also because of the frequency of disease complications associated with frequent visits to the emergency room, this category of patients present some peculiarities. Also, the higher rate of disease complications associated with frequent visits to the emergency room is a factor that associates patients with head and neck cancers with a high risk of SARS-CoV-2 contamination. The concept of using telemedicine services as much as possible, limiting outpatient visits and postponing elective surgery, is also applied to these patients. Although the recommendations of the World Health Organization (WHO) mention the need to regulate the diagnostic and therapeutic approach of cancer patients in this context, the pandemic interaction between cancer and SARS-CoV-2 infection remains unknown, and the factors determining the severity of a possible concomitant evolution are still being investigated. Given the contradiction between the risk of providing treatment for cancer and the risk of disease progresses in the absence of adequate treatment, the concept of ensuring a balance between benefits and risks in terms of cancer treatment during the SARS-CoV-2 pandemic has been implemented. Current data on anticancer treatments and the risk of mortality from COVID-19 causes are contradictory(1,2).

COVID-19 and cancer –
from pathophysio­logical mechanisms
and interactions to clinical reality

The clinical evolution of SARS-CoV-2 infection is different from one case to another and may have the appearance of a subclinical syndrome or a more severe evolution similar to influenza. In some cases, the evo­lu­tion is towards severe pneumonia, with respiratory fai­lure and multiple organ dysfunction (MOTD) or even death. Although advanced age, obesity, diabetes and pre­existing cardiovascular disease are already known to be associated with a risk of a severe form of COVID-19, the as­sociation of cancer with the SARS-CoV-2 infection re­mains unknown. It is difficult to estimate whether cancer is an independent risk factor or the combination of other risk factors and repeated patient exposure through complex treatments in pandemic outbreaks are in fact factors leading to severe developments in these patients. The delay of both surgical and adjuvant oncological treatments has certainly led to a worsening of the condition of these patients, and the effects of these treatments may be a significant factor for a po­ten­tial severity of SARS-CoV-2 co-infection. Also, bio­lo­gical factors related to cancer and the im­mu­no­sup­pressive status associated with this disease, as well as the expressions of transmembrane serine pro­tease 2 (TMPRSS2) and angiotensin-converting en­zyme 2 (ACE2), proinflammatory cytokines and pro­coa­gulant and prothrombotic status increase the risk of complications associated with SARS-CoV-2 infection in cancer patients. While it is unanimously accepted that recent cancer surgery increases the risk of contracting the infection by more than 5% (above the level of risk of contracting the infection in the general population), the evidence for the risk associated with adjuvant treatment is still controversial. Unexpectedly, the higher levels of ACE2 or ACE1/ACE2 rebalancing might improve the outcome of COVID-19 in both sexes by reducing inflammation, thrombosis, and death(3-6).

Some authors consider recent oncological surgery to be associated with an increased rate of mortality and active oncological treatments during the pandemic as being associated with an increased rate (over 5%) of contracting the infection, higher than in the general population. However, there are also opinions that cancer surgery does not increase the risk of COVID-19 mortality in gynecological cancers, but recent immunotherapy treatment may be associated with a high mortality. However, given the heterogeneity of cancer, a generalized hypothesis that cancer patients would have an un­fa­vorable prognosis for SARS-CoV-2 infection might be exa­g­gerated. Comparatively evaluating COVID-19 and non-COVID-19 adult patients in the UK, the authors eva­luated the effect of tumor type, age and sex on patients on the prevalence and mortality of COVID-19 using univariate and multivariable models. 1044 patients with active cancer and documented SARS-CoV-2 infection or COVID-19 disease were registered in the UKCCMP database(1,7).

From the first reports of the pandemic, patients with thoracic tumors are considered at high risk of un­fa­vorable evolution. Old age, a history of smoking and possible preexisting cardiovascular comorbidities make these patients sensitive to the association of SARS-CoV-2 in­fection with cancer. A multicenter observational study in­cluded 200 patients from eight countries, diagnosed or suspected of SARS-CoV-2 infection, between March 26 and 12 April 2020, with all types of chest tumors, who tested positive at the real-time polymerase chain reaction (RT-PCR) or who presented computed tomography ima­ging (CT) suggestive of COVID-19. The median age of the evaluated patients was 68 years old, of which 81% were smokers and 76% were on active cancer treatment at the time of diagnosis of COVID-19. The hospitalization rate was 33% and the death rate was 10% in the lot of patients evaluated in the study. The multivariate analysis showed an increased risk of death associated with age over 65, smoker status and chemotherapy at the time of diagnosis of COVID-19, but the univariate analysis showed only smoking as a risk factor. The au­thors noted a low rate of hospitalization in intensive care units (ICUs), considering that a prediction of severe evolutionary risk and a multidisciplinary approach in order to prioritize the access of these patients to ICUs would reduce the mortality rate(8).

COVID-19 and head and neck cancers

In order to estimate the risk of the association of COVID-19 with head and neck cancers, we must start from some well-known premises. COVID-19 is highly contagious, transmissible and by localizing the virus during the period with the maximum risk of contagion in the nasopharynx and oropharynx, the treatment of head and neck cancers becomes a challenge in the pandemic context. The assessed mortality of COVID-19 during the pandemic outbreak from the USA is approximately 1-2%. Considering that the mortality of head and neck cancers not treated properly is 40-50%, it becomes ob­vious the priority of a cancer treatment even in the pan­de­mic context. However, the procedures that in­clude aerosolization are at high risk of contamination and require special measures, and in case of patients with head and neck cancer the risk is maintained even af­ter performing the procedure by wearing nasogastric tubes, tracheostomy tubes or percutaneous gastrostomy. The association of severe limitation of the access to the specialized medical services, as well as to the hos­pi­tal beds from ICU will favor the progression of the on­co­lo­gi­cal disease and will lead to the increase in the number of serious cases, candidates for a more aggressive treat­ment(9-10).

Most studies that have discussed the problem of head and neck cancers in the pandemic context from the point of view of the surgical approach have evaluated the safety of surgery, given the associated risk of contamination of patients and staff, without analyzing in detail the interaction between cancer and COVID-19. Because this issue has affected most oncology departments, not only of head and neck cancers, but of cancer in general, a situation clearly highlighted in the title of the article “From high volume to zero: Italian experience in the COVID era”, published by Mascangi et al., Baird et al. formulates some basic concepts that should lead the surgical approach to head and neck cancers in the current pandemic context. Given particularly the biological features of squamous cell carcinoma of the head and neck and the aggressive tumor biology at risk of rapid evolution from early-stage disease to local advanced or even metastatic cancer, the context of COVID-19 should not be the cause. In the surgical therapeutic decision of head and neck cancers, factors such as the severity of the disease, the patient’s comorbidities and the local situation of the risk of SARS-CoV-2 infection should be evaluated. The authors also recommend a safe tracheostomy and according to the indications, considering the risk of prolonged intubation or severe sequelae of a possible association of COVID-19.

Retrospectively analyzing data obtained from 1137 patients from 26 countries with head and neck cancer who underwent primary surgery with curative intent, the authors identified a 30-day mortality of 1.2% and a positive SARS-CoV-2 test rate of 3%. Among positive patients, the death rate was estimated at 10.3%, the severe evolution being associated with an advanced disease and ICU admission. The positive SARS-CoV-2 test rate among the surgical team was 3% at 30 days after surgery. These data partially contradict the concept of limiting head and neck surgery during the pandemic, with the authors considering oncological head and neck surgery as safe even in cases where cancer management requires a complex approach. The risk of staff con­ta­mi­nation was significantly higher for patients who pre­sented with oral tumors or tracheostomies. A Danish study evaluated the prevalence of SARS-CoV-2 infection in a tertiary otorhinolaryngology clinic for both patients with suspected acute upper airway and head and neck cancer patients, and the rate of positive patients was 0% in the group including 96 patients operated for head and neck cancer. Thus, in the first six weeks of the first pandemic wave, the authors considered head and neck cancer surgery safe, without any reason to postpone the procedures(14-15).

Day and collaborators recommend managing these surgical risks and evaluating the appropriateness of the nonsurgical treatment option. If traditional surgery is preferred, the authors recommend the use of perioperative protocols in the context of COVID-19 pandemic, in order to reduce the risk of contamination of both patients and staff. Another plea against postponing head and neck cancer surgery is offered by Gupta el al. Referring to the situation in India, a country with an increased incidence of these cancers, they noted that a 1- or 2-month delay in surgery will lead to a high rate of inoperability and the need for extensive oncological surgery of the head and neck. In the context of limiting the diagnostic and therapeutic procedure of this type of cancer, it is foreseeable an increase in the number of cases, social distancing measures being estimated to also have as a consequence a shift to a more advanced disease at the time of the first presentation to the ENT physician(16-20).

The same pathophysiological mechanism involving ACE2 in the pathogenesis of COVID-19 is currently being reported in the case of head and neck cancers by Chauhan et al. The authors also present the SARS-CoV-2 infection mechanism that describes the role of Furin host enzymes in the interaction with the protein S and ACE2 receptor, mentioning the increase in FURIN and ACE2 expression in oral cancer and paracarcinoma tissue. Thus, the hypothesis of an increased risk of infection can be issued through these mechanisms in patients with cancers of the oral cavity. The lack of concrete systematized data regarding the possible impact of the association of COVID-19 makes Sean Dolan ask a rhetorical question about the impact of SARS-CoV-2 infection on patients with squamous cell carcinoma. The author mentions a possible increased risk of combining the two diseases but recommends avoiding smoking, alcohol ingestion, as well as rigorous oral hygiene as safe measures that can help reduce the synergistic impact of cancer and COVID-19. Silverman and collaborators add to these measures the aggressive management of associated comorbidities and note the risk of respiratory complications in this group of patients(21-22).


Due to the risk of shift towards an increased pre­va lence of more advanced stages and consequently towards an increased mortality in case of postponement of surgical treatment, but also of adjuvant treatment, head and neck cancer, and in particular HNSCC, is an oncological pathology that must be prioritized from the point of view of assessment and treatment, even at the time of possible pandemic outbreaks. It is thus es­timated an increase in the need for more extensive sur­gical treatments and definitive nonsurgical treat­ments. Data on the association of SARS-CoV-2 in­fec­tion with head and neck cancer are limited to case studies, with more severe progression anticipated by pos­sible severe pneumonia and associated diseases de­com­pen­sation, and less by the effects associated with a “cy­tokine storm”, given the immunosuppressive status as­so­ciated with cancer. An increased attention to the risk of SARS-CoV-2 infection is needed for oral cavity can­cers, taking into account the possible molecular mecha­nisms involved. Measures to reduce alcohol con­sumption, smoking and strict oral hygiene, as well as the aggressive management of comorbidities and the im­mediate practice of tracheostomy in the case of a clear indication – head and neck cancer patients risking a possible prolonged hospitalization in the ICU in case of a SARS-CoV-2 infection – are measures that can reduce the mortality. It is necessary to evaluate in clinical trials lots of patients who associate head and neck cancer with COVID-19 in order to elucidate both hypotheses based on pathophysiological concepts and to assess the risk of se­vere complications of the possible synergistic effects in case of head and neck cancer association with COVID-19.


  1. Quaquarini E, Saltalamacchia G, Presti D, et al. Impact of COVID-19 Outbreak on Cancer Patient Care and Treatment: Data from an Outpatient Oncology Clinic in Lombardy (Italy). Cancers (Basel). 2020;12(10):2941. 

  2. Lee AKF, Cho RHW, Lau EHL, Cheng HK, Wong EWY, Ku PKM, Chan JYK, Yeung ZWC. Mitigation of head and neck cancer service disruption during COVID-19 in Hong Kong through telehealth and multi-institutional collaboration. Head Neck. 2020 Jul;42(7):1454-1459.

  3. van Dam PA, Huizing M, Mestach G, Dierckxsens S, Tjalma W, Trinh XB, Papadimitriou K, Altintas S, Vermorken J, Vulsteke C, Janssens A, Berneman Z, Prenen H, Meuris L, Vanden Berghe W, Smits E, Peeters M. SARS-CoV-2 and cancer: Are they really partners in crime? Cancer Treat Rev. 2020 Sep;89:102068.

  4. Ravaioli S, Tebaldi M, Fonzi E, et al. ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-CoV-2 in Cancer Patients. Cell Transplant. 2020;29:963689720968749. 

  5. Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males? Int J Mol Sci. 2020 May 14;21(10):3474.

  6. Garde Noguera J, Jantus-Lewintre E, Gil-Raga M, Evgenyeva E, Maciá Escalante S, Llombart-Cussac A, Camps Herrero C. Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis. Mol Clin Oncol. 2017 Mar;6(3):403-408.

  7. Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, Booth S, Campton NA, Cheng VWT, Collins G, Curley HM, Earwaker P, Fittall MW, Gennatas S, Goel A, Hartley S, Hughes DJ, Kerr D, Lee AJX, Lee RJ, Lee SM, Mckenzie H, Middleton CP, Murugaesu N, Newsom-Davis T, Olsson-Brown AC, Palles C, Powles T, Protheroe EA, Purshouse K, Sharma-Oates A, Sivakumar S, Smith AJ, Topping O, Turnbull CD, Várnai C, Briggs ADM, Middleton G, Kerr R; UK Coronavirus Cancer Monitoring Project Team. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020 Oct;21(10):1309-1316.

  8. Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranel J, De Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, Grossi F, Grosso F, Intagliata S, La Verde N, Liu SV, Mazieres J, Mercadante E, Michielin O, Minuti G, Moro-Sibilot D, Pasello G, Passaro A, Scotti V, Solli P, Stroppa E, Tiseo M, Viscardi G, Voltolini L, Wu YL, Zai S, Pancaldi V, Dingemans AM, Van Meerbeeck J, Barlesi F, Wakelee H, Peters S, Horn L; TERAVOLT investigators. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020 Jul;21(7):914-922.

  9. Yuen E, Fote G, Horwich P, et al. Head and neck cancer care in the COVID-19 pandemic: A brief update. Oral Oncol. 2020;105:104738. 

  10. Civantos AM, Carey RM, Lichtenstein GR, Lukens JN, Cohen RB, Rassekh CH. Care of immunocompromised patients with head and neck cancer during the COVID-19 pandemic: Two challenging and informative clinical cases. Head Neck. 2020 Jun;42(6):1131-1136.

  11. Mascagni D, Eberspacher C, Mascagni P, Arezzo A, Selvaggi F, Sturiale A, Milito G, Naldini G. From high volume to “zero” proctology: Italian experience in the COVID era. Int J Colorectal Dis. 2020 Sep;35(9):1777-1780.

  12. Baird BJ, Sung CK. Coronavirus Disease-19: Challenges Associated with the Treatment of Head and Neck Oncology and Laryngology Patients in the Coronavirus Disease-19 Era. Otolaryngol Clin North Am. 2020;53(6):1159-1170. 

  13. COVID Surg Collaborative. Head and neck cancer surgery during the COVID-19 pandemic: An international, multicenter, observational cohort study. Cancer. 2020 Dec 21. doi: 10.1002/cncr.33320.

  14. Andersen PA, Rasmussen KMB, Channir HI, von Buchwald C, Cayé-Thomasen P, Klokker M, Knudsen JD, Kirkby NS, Aanaes K, Jensen RG. The impact and prevalence of SARS-CoV-2 in patients with head and neck cancer and acute upper airway infection in a tertiary otorhinolaryngology referral center in Denmark. Eur Arch Otorhinolaryngol. 2021 Jan 3;1-7.  

  15. Day AT, Sher DJ, Lee RC, Truelson JM, Myers LL, Sumer BD, Stankova L, Tillman BN, Hughes RS, Khan SA, Gordin EA. Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks. Oral Oncol. 2020 Jun;105:104684.

  16. Fakhry N, Schultz P, Morinière S, Breuskin I, Bozec A, Vergez S, de Garbory L, Hartl D, Temam S, Lescanne E, Couloigner V, Barry B; French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL); French Society of Head and Neck Carcinology (SFCCF). French consensus on management of head and neck cancer surgery during COVID-19 pandemic. Eur Ann Otorhinolaryngol Head Neck Dis. 2020 May;137(3):159-160.

  17. Gupta A, Arora V, Nair D, Agrawal N, Su YX, Holsinger FC, Chan JYK. Status and strategies for the management of head and neck cancer during COVID-19 pandemic: Indian scenario. Head Neck. 2020 Jul;42(7):1460-1465.

  18. Bowman R, Crosby DL, Sharma A. Surge after the surge: Anticipating the increased volume and needs of patients with head and neck cancer after the peak in COVID-19. Head Neck. 2020 Jul;42(7):1420-1422.

  19. Mannelli G, Santoro R, Bonomo P, Desideri I, Spinelli G. Will a tumor pandemic come after the COVID-19 pandemic? Head and Neck cancer perspective. Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8573-8575.

  20. Chauhan A, Ghoshal S, Pal A. Increased susceptibility of SARS-CoV2 infection on oral cancer patients; cause and effects: An hypothesis. Med Hypotheses. 2020;144:109987. 

  21. Dolan S. What is the impact of COVID-19 on head and neck squamous cell carcinoma patients? Evid Based Dent. 2020 Jun;21(2):52-53. 

  22. Silverman DA, Lin C, Tamaki A, Puram SV, Carrau RL, Seim NB, Eskander A, Rocco JW, Old MO, Kang SY. Respiratory and pulmonary complications in head and neck cancer patients: Evidence-based review for the COVID-19 era. Head Neck. 2020 Jun;42(6):1218-1226.

Articole din ediţiile anterioare

CASE PRESENTATION | Ediţia 1 58 / 2022

Fighting disease at 83 years old: SARS-CoV-2 survival and response to anti-PD-1 therapy in PD-L1 negative adenocarcinoma of the lung – case report

Maria Nedelcu, Adelina Silvana Dragomir, Elena Adriana Mateianu, Conf. dr. Dana Lucia Stănculeanu

În timpul pandemiei de COVID-19, supra­vie­ţui­rea totală medie a pacienţilor cu cancer pulmonar a scăzut de la 7,9 luni la 6,7 luni. În analiza TE...

25 martie 2022
RADIOTHERAPY | Ediţia 1 54 / 2021

Reiradierea cancerelor de cap şi gât în era imunoterapiei

Ciprian Camil Mireştean, Anda Crişan, Liliana Eleonora Semenescu, Irina Roxana Iancu, Dragoş Petru Teodor Iancu

Cu toate că în ultimii ani s-au înregistrat progrese semnificative în ceea ce priveşte terapia modernă multidisciplinară pen­tru cancerele de cap ş...

24 martie 2021
PALLIATIVE CARE | Ediţia 3 56 / 2021

Îngrijirile paliative – prezent şi viitor

CSI Dr. Abil. Alexandru Grigorescu

Îngrijirile paliative iau o amploare din ce în ce mai mare în în­trea­ga lume, iar pandemia de COVID-19 a accentuat nevoia pentru astfel de îngrijiri.

25 octombrie 2021
REVIEW | Ediţia 2 51 / 2020

Managementul tratamentului şi urmărirea pacienţilor cu cancer de sân în perioada pandemiei de COVID-19

Daniela Zob, Conf. dr. Dana Lucia Stănculeanu, Mădălina Drăgănescu, Prof. Dr. Laura Mazilu, Cornelia Niţipir, Amalia Constantinescu, Gabriela Niculai, Adelina Silvana Gheorghe, Andreea-Daniela Gheorghe, Alexandru BLIDARU

Cancerul mamar ocupă locul întâi în privinţa tipurilor de neo­pla­zie întâlnite la sexul feminin la nivel global, fiind a doua cau­ză de can­cer in...

19 mai 2020